BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioAxone Therapeutic Inc. Announces Closing Of $5.1 Million


12/19/2005 10:26:22 AM

MONTREAL, Dec. 19 /PRNewswire/ - BioAxone Therapeutic Inc., a Montreal- based neuroscience company, is pleased to announce the recent closing of $5.1 M, the last tranche of a second-round investment of $12.15 M, fully subscribed by its current investors T2C2/Bio2000, Solidarity Fund QFL, Desjardins Venture Capital and Lothian Partners 27 SARL. The investment was made following the completion of key milestones related to the Company's on- going phase I/IIa clinical trial in acute spinal cord injury (SCI), as well as progress in corporate development. Since the trial's initiation in February of this year, 20 patients have been enrolled in 10 U.S. and Canadian sites.

"BioAxone is making rapid progress in advancing the clinical development of its small and large molecule drug candidates in spinal cord injury and eye diseases", said Frank Bobe, President and CEO. "This recent investment will allow us to complete our phase I/IIa clinical trial in acute spinal cord injury by June of next year, and advance to a phase IIb/III trial before the end of 2006."

BioAxone Therapeutic Inc. is a privately owned neuroscience company specializing in the development and commercialization of proprietary technologies that target Rho signaling. The Company has one product in clinical development for the treatment of acute spinal cord injury and several product candidates in preclinical phase for the treatment of age-related macular degeneration and glaucoma. Established in April 2000 and headquartered in Montreal, Canada, BioAxone has demonstrated expertise in recombinant protein product development and has a focused small molecule program.

Source: BIOAXONE THERAPEUTIC INC.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES